Compounds > 2-butanone oxime
Page last updated: 2024-11-05

2-butanone oxime

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

2-Butanone oxime, also known as methyl ethyl ketone oxime, is a colorless liquid with a characteristic odor. It is a versatile chemical used in various applications, including the synthesis of pharmaceuticals, pesticides, and other organic compounds. It is also used as a reagent in analytical chemistry and as an intermediate in the production of various industrial chemicals. The synthesis of 2-butanone oxime typically involves the reaction of 2-butanone with hydroxylamine. It is a relatively stable compound, but it can decompose under certain conditions. The effects of 2-butanone oxime on living organisms are not well-studied, but it is known to be irritating to the skin and eyes. It is important to handle this compound with care and to follow safety precautions.'

2-butanone oxime: RN in first source; used extensively in paints, resins & adhesives [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID7292
CHEMBL ID3181847
MeSH IDM0273537

Synonyms (22)

Synonym
methylethylketoxime
96-29-7
2-butanone oxime
ethyl methyl ketoxime
2-butanone, oxime
methyl ethyl ketoxime
B0688
n-butan-2-ylidenehydroxylamine
dtxsid1021821 ,
FT-0611623
AKOS017263158
methylethyl ketoxime
ethylmethyl-ketoxime
methylethylketone oxime
skino no. 2
aron m 1
2-butoxime
skino 2
pentan-2-one,oxime
butan-2-one, oxime
CHEMBL3181847
(e)-butan-2-one oxime

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" There was no adult "no observable adverse effect level" (NOAEL) established; the NOAEL for reproductive and postnatal toxicity was at least 200 mg/kg/day for rats in this study."( Reproductive toxicity evaluation of methylethyl ketoxime by gavage in CD rats.
Brine, DR; Derelanko, MJ; Gerhart, JM; Gilliam, AF; Marr, MC; Myers, CB; Rinehart, WE; Seely, JC; Tyl, RW, 1996)		0.29

Dosage Studied

ExcerptRelevanceReference
" Thirty-eight-week-old rats/sex/group (F0) were administered MEKO in water, by gavage, at 0, 10, 100, or 200 mg/kg/day (at a dosing volume of 2 ml/kg), 5 days/week for 10 weeks with vaginal cytology evaluation (VCE) of F0 females during the last 3 weeks of the prebreed period."( Reproductive toxicity evaluation of methylethyl ketoxime by gavage in CD rats.
Brine, DR; Derelanko, MJ; Gerhart, JM; Gilliam, AF; Marr, MC; Myers, CB; Rinehart, WE; Seely, JC; Tyl, RW, 1996)		0.29
" Following preliminary dose range finding studies, groups of 25 pregnant rats or 18 pregnant rabbits were dosed by gavage with aqueous solutions of MEKO at 0, 60, 200, or 600 mg/kg (rats) or 0, 8, 14, 24, or 40 mg/kg (rabbits) on gestation days 6-15 or 6-18, respectively."( Developmental toxicity studies of methyl ethyl ketoxime (MEKO) in rats and rabbits.
Derelanko, MJ; Rinehart, WE; Rodwell, DE, 2003)		0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (44.44)18.2507
2000's4 (44.44)29.6817
2010's1 (11.11)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
hydroxylamine
amino alcohol : An alcohol containing an amino functional group in addition to the alcohol-defining hydroxy group.		1.9910hydroxylaminesalgal metabolite;
bacterial xenobiotic metabolite;
EC 1.1.3.13 (alcohol oxidase) inhibitor;
EC 4.2.1.22 (cystathionine beta-synthase) inhibitor;
EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor;
nitric oxide donor;
nucleophilic reagent
cyclohexanone oxime
[no description available]		1.9910
tiletamine hydrochloride
Cyclohexanones: Cyclohexane ring substituted by one or more ketones in any position.. cyclohexanones : Any alicyclic ketone based on a cyclohexane skeleton and its substituted derivatives thereof.		1.9910
acetoxime
[no description available]		210ketoxime
acetaldehyde oxime
acetaldehyde oxime: structure. (E)-acetaldehyde oxime : The (E)-stereoisomer of acetaldehyde oxime.. acetaldehyde oxime : An aldoxime derived from acetaldehyde.		1.9910acetaldehyde oxime
ConditionIndicatedRelationship StrengthStudiesTrials
Fetal Resorption
The disintegration and assimilation of the dead FETUS in the UTERUS at any stage after the completion of organogenesis which, in humans, is after the 9th week of GESTATION. It does not include embryo resorption (see EMBRYO LOSS).		02.0110
Complications, Pregnancy
[description not available]		02.0110
Abnormalities, Drug-Induced
Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.		02.0110
Anemia
A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.		02.730
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		02.0110
Narcosis
A state of depressed CENTRAL NERVOUS SYSTEM marked by stupor or insensibility.		02.0410
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		0210
Experimental Neoplasms
[description not available]		0210